{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T20:06:29Z","timestamp":1766088389301,"version":"3.37.3"},"reference-count":24,"publisher":"Consilium Medicum","issue":"11","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Terapevticheskii arkhiv"],"abstract":"<jats:p>Often ill people are, first of all, patients with recurrent infectious and inflammatory diseases of the upper respiratory tract (URT). They put a significant financial burden on the healthcare system. The leading etiological factors of recurrent inflammatory diseases of URT, in addition to pathogenic bacterial microflora, are viral agents (viruses of the viral respiratory infections group, herpes viruses). The chronic infection and recurrence of local inflammation is due to the persistence of resident bacterial and viral flora (including herpes viruses), and as a result, the insufficiency of the mucosal immune response. In order to optimize therapeutic and preventive measures for frequently ill adults and children, the most promising is the use of immunotherapy and immunoprophylaxis. The immunomodulator inosine pranobex, due to its unique combined (immunotropic and antiviral) properties, demonstrates effectiveness in the complex treatment of viral respiratory infections, including in combination with herpes viruses, and is successfully used to prevent frequent relapses of infectious and inflammatory diseases of the URT. The domestic analogue of inosine pranobex Normomed\u00ae [JSC \"Valenta Pharm\"\u00bb, \u041b\u041f-\u2116(002470)-(\u0420\u0413-RU), \u041b\u041f-\u2116(005542)-(\u0420\u0413-RU)], has a good safety and bioequivalence profile, and occupies a worthy field in the Russian pharmaceutical market among drugs recommended for the treatment of viral infections in adults and children.<\/jats:p>","DOI":"10.26442\/00403660.2024.11.203033","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T10:43:58Z","timestamp":1734345838000},"page":"1076-1082","source":"Crossref","is-referenced-by-count":4,"title":["Issues of treatment and prevention of recurrent inflammatory diseases of the upper respiratory tract: An immunologist's view. A review"],"prefix":"10.26442","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-9350","authenticated-orcid":false,"given":"Andrei E.","family":"Shul'zhenko","sequence":"additional","affiliation":[{"name":"NRC Institute of Immunology FMBA of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9373-4681","authenticated-orcid":false,"given":"Irina N.","family":"Zuikova","sequence":"additional","affiliation":[{"name":"NRC Institute of Immunology FMBA of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-9831","authenticated-orcid":false,"given":"Rosalia V.","family":"Shchubelko","sequence":"additional","affiliation":[{"name":"NRC Institute of Immunology FMBA of Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"unstructured":"\u0413\u0443\u043b\u044f\u0435\u0432\u0430 \u0421.\u0424., \u0426\u0435\u043d\u0435\u043a\u043e\u0432 \u0410.\u0421., \u0428\u0438\u0445\u043e\u0432\u0430 \u0415.\u0412., \u0413\u0443\u043b\u044f\u0435\u0432 \u041f.\u0412. \u0414\u0438\u0441\u043f\u0430\u043d\u0441\u0435\u0440\u0438\u0437\u0430\u0446\u0438\u044f \u0447\u0430\u0441\u0442\u043e \u0438 \u0434\u043b\u0438\u0442\u0435\u043b\u044c\u043d\u043e \u0431\u043e\u043b\u0435\u044e\u0449\u0438\u0445: \u044d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u044b\u0439 \u043f\u0443\u0442\u044c \u0441\u043d\u0438\u0436\u0435\u043d\u0438\u044f \u043f\u043e\u0442\u0435\u0440\u044c \u043f\u043e \u0432\u0440\u0435\u043c\u0435\u043d\u043d\u043e\u0439 \u043d\u0435\u0442\u0440\u0443\u0434\u043e\u0441\u043f\u043e\u0441\u043e\u0431\u043d\u043e\u0441\u0442\u0438 \u0432 \u0440\u0430\u043c\u043a\u0430\u0445 \u0440\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u043e\u0433\u043e \u043d\u0430\u0446\u0438\u043e\u043d\u0430\u043b\u044c\u043d\u043e\u0433\u043e \u043f\u0440\u043e\u0435\u043a\u0442\u0430 \u00ab\u0417\u0434\u043e\u0440\u043e\u0432\u044c\u0435\u00bb. \u0412\u044f\u0442\u0441\u043a\u0438\u0439 \u043c\u0435\u0434\u0438\u0446\u0438\u043d\u0441\u043a\u0438\u0439 \u0432\u0435\u0441\u0442\u043d\u0438\u043a. 2011;31(1):12-6 [Gulyaeva SF, Tsenekov AS, Shikhova YeV, Gulyaev PV. Clinical examination of frequently and often ill patients as an effective way to decrease losses on temporary disability within the limits of the Russian National Project \"Health\". Medical Newsletter of Vyatka. 2011;31(1):12-6 (in Russian)].","key":"ref1"},{"unstructured":"\u0413\u043e\u043d\u0447\u0430\u0440\u043e\u0432\u0430 \u041e.\u0412., \u041a\u0443\u0440\u0430\u043d\u043e\u0432 \u0413.\u0412. \u0421\u043e\u0432\u0440\u0435\u043c\u0435\u043d\u043d\u044b\u0435 \u043f\u043e\u0434\u0445\u043e\u0434\u044b \u043a \u043b\u0435\u0447\u0435\u043d\u0438\u044e \u0447\u0430\u0441\u0442\u043e \u0431\u043e\u043b\u0435\u044e\u0449\u0438\u0445 \u0434\u0435\u0442\u0435\u0439. \u041f\u0440\u0430\u043a\u0442\u0438\u043a\u0430 \u043f\u0435\u0434\u0438\u0430\u0442\u0440\u0430. 2016;1:24-9 [Goncharova OV, Kuranov GV. Modern approaches to the treatment of frequently ill children. Paediatrician Practice. 2016;1:24-9 (in Russian)].","key":"ref2"},{"unstructured":"\u041e\u0441\u0442\u0440\u044b\u0435 \u0440\u0435\u0441\u043f\u0438\u0440\u0430\u0442\u043e\u0440\u043d\u044b\u0435 \u0432\u0438\u0440\u0443\u0441\u043d\u044b\u0435 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 (\u041e\u0420\u0412\u0418) \u0443 \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445. \u041a\u043b\u0438\u043d\u0438\u0447\u0435\u0441\u043a\u0438\u0435 \u0440\u0435\u043a\u043e\u043c\u0435\u043d\u0434\u0430\u0446\u0438\u0438. \u041c., 2022. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/cr.minzdrav.gov.ru\/schema\/724_1?ysclid=m2u4dkdvoj763299328. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 25.08.2024 [Ostrye respiratornye virusnye infektsii (ORVI) u vzroslykh. Klinicheskie rekomendatsii. Moscow, 2022. Available at: https:\/\/cr.minzdrav.gov.ru\/schema\/724_1?ysclid=m2u4dkdvoj763299328. Accessed: 25.08.2024 (in Russian)].","key":"ref3"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.17116\/terarkh201890122-26"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.26442\/00403660.2021.11.201191"},{"unstructured":"\u041a\u0440\u044e\u043a\u043e\u0432 \u0410.\u0418., \u0422\u0443\u0440\u043e\u0432\u0441\u043a\u0438\u0439 \u0410.\u0411., \u041a\u043e\u043b\u0431\u0430\u043d\u043e\u0432\u0430 \u0418.\u0413., \u041a\u0443\u0434\u0440\u044f\u0432\u0446\u0435\u0432\u0430 \u042e.\u0421. \u041e\u0441\u043e\u0431\u0435\u043d\u043d\u043e\u0441\u0442\u0438 \u0442\u0435\u0447\u0435\u043d\u0438\u044f \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u043e\u043d\u043d\u043e\u0433\u043e \u043f\u0440\u043e\u0446\u0435\u0441\u0441\u0430 \u043f\u0440\u0438 \u043f\u0430\u0442\u043e\u043b\u043e\u0433\u0438\u0438 \u0432\u0435\u0440\u0445\u043d\u0438\u0445 \u0434\u044b\u0445\u0430\u0442\u0435\u043b\u044c\u043d\u044b\u0445 \u043f\u0443\u0442\u0435\u0439. \u0420\u041c\u0416. 2016;21:1399-402 [Kryukov AI, Turovskiy AB, Kolbanova IG, Kudryavtseva YuS. Infectious disease in upper respiratory tract disorders. RMJ. 2016;21:1399-402 (in Russian)].","key":"ref6"},{"unstructured":"\u0417\u0443\u0439\u043a\u043e\u0432\u0430 \u0418.\u041d., \u0429\u0443\u0431\u0435\u043b\u043a\u043e \u0420.\u0412., \u0428\u0443\u043b\u044c\u0436\u0435\u043d\u043a\u043e \u0410.\u0415. \u0418\u043c\u043c\u0443\u043d\u043e\u0441\u0443\u043f\u0440\u0435\u0441\u0441\u0438\u0432\u043d\u0430\u044f \u0440\u043e\u043b\u044c \u043c\u0438\u043a\u0440\u043e\u0431\u0438\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u043e\u0433\u043e \u043f\u0435\u0439\u0437\u0430\u0436\u0430 \u0432\u0435\u0440\u0445\u043d\u0438\u0445 \u0434\u044b\u0445\u0430\u0442\u0435\u043b\u044c\u043d\u044b\u0445 \u043f\u0443\u0442\u0435\u0439 \u0443 \u0447\u0430\u0441\u0442\u043e \u0431\u043e\u043b\u0435\u044e\u0449\u0438\u0445 \u0432\u0437\u0440\u043e\u0441\u043b\u044b\u0445. \u0420\u043e\u0441\u0441\u0438\u0439\u0441\u043a\u0438\u0439 \u0430\u043b\u043b\u0435\u0440\u0433\u043e\u043b\u043e\u0433\u0438\u0447\u0435\u0441\u043a\u0438\u0439 \u0436\u0443\u0440\u043d\u0430\u043b. 2018;15(1S):40-4 [Shchubelko RV, Zuikova IN, Shuljenko AE. Immunosuppressive role of the microflora of the upper respiratory tract in the frequently affected adult patients. Russian Journal of Allergy. 2018;15(1S):40-4 (in Russian)].","key":"ref7"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.24411\/0206-4952-2019-11004"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.18821\/0206-4952-2018-39-1-81-88"},{"unstructured":"\u0420\u0430\u043d\u0434\u043e\u043c\u0438\u0437\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0435 \u043f\u0435\u0440\u0435\u043a\u0440\u0435\u0441\u0442\u043d\u043e\u0435 \u0434\u0432\u0443\u0445\u043f\u0435\u0440\u0438\u043e\u0434\u043d\u043e\u0435 \u0438\u0441\u0441\u043b\u0435\u0434\u043e\u0432\u0430\u043d\u0438\u0435 \u0431\u0438\u043e\u044d\u043a\u0432\u0438\u0432\u0430\u043b\u0435\u043d\u0442\u043d\u043e\u0441\u0442\u0438 \u0441 \u0430\u0434\u0430\u043f\u0442\u0438\u0432\u043d\u044b\u043c \u0434\u0438\u0437\u0430\u0439\u043d\u043e\u043c \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432 \u0418\u043d\u043e\u0437\u0438\u043d, \u0442\u0430\u0431\u043b\u0435\u0442\u043a\u0438 500 \u043c\u0433 (\u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b\u044c: \u0410\u041e \u00ab\u0424\u0430\u0440\u043c\u0430\u0441\u0438\u043d\u0442\u0435\u0437\u00bb, \u0420\u043e\u0441\u0441\u0438\u044f; \u0434\u0435\u0440\u0436\u0430\u0442\u0435\u043b\u044c \u0420\u0423: \u043d\u0435 \u043f\u0440\u0438\u043c\u0435\u043d\u0438\u043c\u043e), \u0438 Isoprinosine, \u0442\u0430\u0431\u043b\u0435\u0442\u043a\u0438 500 \u043c\u0433 (\u043f\u0440\u043e\u0438\u0437\u0432\u043e\u0434\u0438\u0442\u0435\u043b\u044c: EWOPHARMA AG ROMANIA, \u0420\u0443\u043c\u044b\u043d\u0438\u044f; \u0434\u0435\u0440\u0436\u0430\u0442\u0435\u043b\u044c \u0420\u0423: EWOPHARMA INTERNATIONAL S.R.O) \u0443 \u0437\u0434\u043e\u0440\u043e\u0432\u044b\u0445 \u0434\u043e\u0431\u0440\u043e\u0432\u043e\u043b\u044c\u0446\u0435\u0432 \u043f\u043e\u0441\u043b\u0435 \u043e\u0434\u043d\u043e\u043a\u0440\u0430\u0442\u043d\u043e\u0433\u043e \u043f\u0440\u0438\u0435\u043c\u0430 \u043a\u0430\u0436\u0434\u043e\u0433\u043e \u0438\u0437 \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u043e\u0432 \u043f\u043e\u0441\u043b\u0435 \u0435\u0434\u044b. \u0420\u0435\u0436\u0438\u043c \u0434\u043e\u0441\u0442\u0443\u043f\u0430: https:\/\/grlsbase.ru\/clinicaltrails\/mnn\/205\/cltr?page=2. \u0421\u0441\u044b\u043b\u043a\u0430 \u0430\u043a\u0442\u0438\u0432\u043d\u0430 \u043d\u0430 25.08.2024 [Randomizirovannoe perekrestnoe dvukhperiodnoe issledovanie bioekvivalentnosti s adaptivnym dizainom preparatov Inozin, tabletki 500 mg (proizvoditel': AO \u00abFarmasintez\u00bb, Rossiia; derzhatel' RU: ne primenimo), i Isoprinosine, tabletki 500 mg (proizvoditel': EWOPHARMA AG ROMANIA, Rumyniia; derzhatel' RU: EWOPHARMA INTERNATIONAL S.R.O) u zdorovykh dobrovol'tsev posle odnokratnogo priema kazhdogo iz preparatov posle edy. Available at: https:\/\/grlsbase.ru\/clinicaltrails\/mnn\/205\/cltr?page=2. Accessed: 25.08.2024 (in Russian)].","key":"ref10"},{"unstructured":"\u0421\u0430\u0432\u0435\u043d\u043a\u043e\u0432\u0430 \u041c.\u0421., \u0411\u0430\u043b\u0430\u043a\u0438\u0440\u0435\u0432\u0430 \u0413.\u041c., \u0420\u0443\u043c\u044f\u043d\u0446\u0435\u0432\u0430 \u0418.\u0413. \u041f\u043e\u043a\u0430\u0437\u0430\u043d\u0438\u044f \u0438 \u043e\u043f\u044b\u0442 \u043f\u0440\u0438\u043c\u0435\u043d\u0435\u043d\u0438\u044f \u0438\u043d\u043e\u0437\u0438\u043d\u0430 \u043f\u0440\u0430\u043d\u043e\u0431\u0435\u043a\u0441\u0430 \u0432 \u043f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u043f\u0440\u0430\u043a\u0442\u0438\u043a\u0435. \u041f\u0435\u0434\u0438\u0430\u0442\u0440\u0438\u044f. Consilium Medicum. 2017;4:52-5 [Savenkova MS, Balakireva GM, Rumyantseva IG. Indications and experience in the use of inosine pranobex in pediatric practice. Pediatrics. Consilium Medicum. 2017;4:52-5 (in Russian)].","key":"ref11"},{"unstructured":"Majewska A, Lasek W, M\u0142ynarczyk G. Inosine pranobex \u2013 cytotoxic activities and effect of on replication of human parainfluenza viruses (HPIV-2, HPIV-4), entroviruses (CA16, EV71) and adenoviruses (HAdV-2, HAdV-5) in vitro. Med Dosw Mikrobiol. 2015;67(2):107-13. PMID:26591662","key":"ref12"},{"doi-asserted-by":"crossref","unstructured":"Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. Drugs. 1986;32(5):383-24. PMID:2431857","key":"ref13","DOI":"10.2165\/00003495-198632050-00001"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1007\/s12325-019-00995-6"},{"doi-asserted-by":"crossref","unstructured":"Gordon P, Brown ER. The antiviral activity of Isoprinosine. Can J Microbiol. 1972;18(9):1463-70. PMID:4341918","key":"ref15","DOI":"10.1139\/m72-224"},{"doi-asserted-by":"crossref","unstructured":"Waldman RH, Ganguly R. Therapeutic efficacy of inosiplex (Isoprinosine) in rhinovirus infection. Ann N Y Acad Sci. 1977;284:153-60. PMID:81636","key":"ref16","DOI":"10.1111\/j.1749-6632.1977.tb21946.x"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.3390\/v13112246"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1186\/s12879-016-1973-7"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.47460\/uct.v24i103.356"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.20953\/1817-7646-2018-5-74-82"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.32364\/2587-6821-2023-7-11-2"},{"doi-asserted-by":"crossref","unstructured":"\u0421\u0438\u043c\u043e\u0432\u0430\u043d\u044c\u044f\u043d \u042d.\u041d., \u0414\u0435\u043d\u0438\u0441\u0435\u043d\u043a\u043e \u0412.\u0411., \u0413\u0440\u0438\u0433\u043e\u0440\u044f\u043d \u0410.\u0412. \u042d\u0444\u0444\u0435\u043a\u0442\u0438\u0432\u043d\u043e\u0441\u0442\u044c \u043a\u043e\u043c\u043f\u043b\u0435\u043a\u0441\u043d\u043e\u0433\u043e \u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043d\u0438\u044f \u0438\u043d\u043e\u0437\u0438\u043d\u0430 \u043f\u0440\u0430\u043d\u043e\u0431\u0435\u043a\u0441\u0430 \u0438 \u0440\u0435\u043a\u043e\u043c\u0431\u0438\u043d\u0430\u043d\u0442\u043d\u043e\u0433\u043e \u0438\u043d\u0442\u0435\u0440\u0444\u0435\u0440\u043e\u043d\u0430-\u03b12\u03b2 \u043f\u0440\u0438 \u0445\u0440\u043e\u043d\u0438\u0447\u0435\u0441\u043a\u043e\u0439 \u042d\u043f\u0448\u0442\u0435\u0439\u043d\u0430\u2013\u0411\u0430\u0440\u0440 \u0432\u0438\u0440\u0443\u0441\u043d\u043e\u0439 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438 \u0443 \u0447\u0430\u0441\u0442\u043e \u0431\u043e\u043b\u0435\u044e\u0449\u0438\u0445 \u0434\u0435\u0442\u0435\u0439. \u0414\u0435\u0442\u0441\u043a\u0438\u0435 \u0438\u043d\u0444\u0435\u043a\u0446\u0438\u0438. 2015;14(4):31-45 [Simovanyan EN, Denisenko VB, Grigoryan AV. The effectiveness of complex use of inosine pranobex and recombinant interferon-\u03b12\u03b2 by chronic Epstein\u2013Barr virus infection in frequently ill children. Children Infections. 2015;14(4):31-45 (in Russian)].","key":"ref22","DOI":"10.22627\/2072-8107-2015-14-4-31-45"},{"unstructured":"\u0411\u0435\u043b\u0430\u043d \u042d.\u0411., \u0421\u0430\u0434\u0447\u0438\u043a\u043e\u0432\u0430 \u0422.\u041b., \u041f\u0430\u043d\u0438\u043d\u0430 \u0410.\u0410., \u0438 \u0434\u0440. \u041e\u043f\u0442\u0438\u043c\u0438\u0437\u0430\u0446\u0438\u044f \u0442\u0435\u0440\u0430\u043f\u0438\u0438 \u0440\u0435\u0446\u0438\u0434\u0438\u0432\u0438\u0440\u0443\u044e\u0449\u0435\u0433\u043e \u0440\u0438\u043d\u043e\u0444\u0430\u0440\u0438\u043d\u0433\u0438\u0442\u0430, \u0430\u0441\u0441\u043e\u0446\u0438\u0438\u0440\u043e\u0432\u0430\u043d\u043d\u043e\u0433\u043e \u0441 \u0446\u0438\u0442\u043e\u043c\u0435\u0433\u0430\u043b\u043e\u0432\u0438\u0440\u0443\u0441\u043e\u043c \u0438\u043b\u0438 \u0432\u0438\u0440\u0443\u0441\u043e\u043c \u042d\u043f\u0448\u0442\u0435\u0439\u043d\u0430\u2013\u0411\u0430\u0440\u0440, \u0443 \u0434\u0435\u0442\u0435\u0439. \u0424\u0430\u0440\u043c\u0430\u0442\u0435\u043a\u0430. 2015;14(307):35-40 [Belan EB, Sadchikova TL, Panina AA, et al. Optimization of therapy of recurrent cytomegalovirus- and Epstein\u2013Barr virus-associated rhinopharyngitis in children. Pharmateca Medical Journal. 2015;14(307):35-40 (in Russian)].","key":"ref23"},{"doi-asserted-by":"publisher","key":"ref24","DOI":"10.25587\/SVFU.2021.22.1.006"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"link":[{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/634593\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/viewFile\/634593\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T10:44:26Z","timestamp":1734345866000},"score":1,"resource":{"primary":{"URL":"https:\/\/ter-arkhiv.ru\/0040-3660\/article\/view\/634593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":24,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,12,16]]}},"URL":"https:\/\/doi.org\/10.26442\/00403660.2024.11.203033","relation":{},"ISSN":["2309-5342","0040-3660"],"issn-type":[{"type":"electronic","value":"2309-5342"},{"type":"print","value":"0040-3660"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}